Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,045.25 +26.86 (+0.54%) Dow
38,126.62 +223.33 (+0.59%) Nasdaq
15,745.21 +139.73 (+0.90%) Bitcoin USD
59,113.34 +1,916.64 (+3.35%) CMC Crypto 200
1,272.81 +2.07 (+0.16%)
LLY Jan 2026 370.000 call
| Previous close | 400.00 |
| Open | 400.00 |
| Bid | 413.00 |
| Ask | 421.50 |
| Strike | 370.00 |
| Expiry date | 2026-01-16 |
| Day's range | 400.00 - 400.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
Simply Wall St.Eli Lilly and Company (NYSE:LLY) Just Released Its First-Quarter Earnings: Here's What Analysts Think
It's been a good week for Eli Lilly and Company ( NYSE:LLY ) shareholders, because the company has just released its...
Barrons.comNovo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
The Danish pharmaceutical giant, which became Europe’s most valuable company last year, said Wegovy sales jumped 106% in the first quarter.
- Reuters
UPDATE 7-Novo Nordisk trims price for blockbuster obesity drug as competition heats up
Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while competition from rival Eli Lilly forced the company to cut prices of the drug, knocking its shares. These are Novo's second set of results since Lilly launched obesity drug Zepbound in the United States in December and highlight the fast-changing dynamics as the two companies go head to head in a market which analysts estimate could be worth as much as $100 billion by the end of the decade. Prices for Wegovy and diabetes treatment Ozempic, which contains the same active ingredient, fell in the first quarter amid increased volumes and competition, the company's chief financial officer Karsten Munk Knudsen told analysts on a call.
